Management of Stable Angina

Diagnostic Approach

• The European Society of Cardiology recommends exercise ECG as the initial non-invasive test of choice to confirm diagnosis and determine prognosis in patients with stable angina 1
• Alternative investigations such as myocardial perfusion scintigraphy and stress echocardiography are valuable when exercise ECG is not possible or interpretable, or to demonstrate the extent and localization of myocardial ischemia 1
• Echocardiography and other non-invasive imaging modalities help evaluate ventricular function in patients with stable angina 1
• Careful interpretation of chest pain is particularly important in women with stable angina, as classical symptoms may be less reliable indicators of coronary disease compared to men 2

Risk Factor Modification

• The European Society of Cardiology recommends lifestyle modification alongside pharmacological intervention after initial risk evaluation for patients with stable angina 3
• Strict diabetic control, weight management, smoking cessation, and blood pressure control are strongly advised for all patients with coronary disease, including those with stable angina 3
• Successful risk factor management may modify the initial risk assessment for patients with stable angina 3

Pharmacological Management

• The European Society of Cardiology recommends aspirin 75 mg daily for all patients with stable angina without specific contraindications 4
• Statin therapy is recommended for all patients with coronary disease, including those with stable angina 4
• ACE inhibitor therapy is recommended for patients with hypertension, heart failure, LV dysfunction, prior MI with LV dysfunction, or diabetes, and who have stable angina 4
• Beta-blockers are recommended for post-MI patients or those with heart failure and stable angina 4
• Short-acting nitrates are recommended for immediate symptom relief and situational prophylaxis in patients with stable angina 3, 5
• Beta-blockers are recommended as first-line therapy at optimal doses for patients with stable angina: bisoprolol 10 mg once daily, metoprolol CR 200 mg once daily, or atenolol 100 mg daily 6, 5
• If beta-blockers are contraindicated or not tolerated, calcium channel blockers or long-acting nitrates are recommended as alternatives for patients with stable angina 3
• Anti-anginal drug treatment should be tailored to individual needs, with optimization of one drug's dosing before adding another for patients with stable angina 3
• It is advisable to switch drug combinations before attempting a three-drug regimen for patients with stable angina 3

Revascularization

• Coronary arteriography should be undertaken when symptoms are not satisfactorily controlled by medical means, with a view to revascularization for patients with stable angina 3
• PCI is effective for patients with angina not satisfactorily controlled by medical treatment when anatomically suitable lesions are present 3
• CABG is highly effective for symptom relief and reduces mortality risk in specific subgroups, such as left main stem stenosis, proximal LAD stenosis, or three-vessel disease with impaired LV function, and who have stable angina 3

Common Pitfalls to Avoid

• Using three anti-anginal drugs simultaneously may provide less symptomatic protection than two drugs for patients with stable angina 5
• Immediate-release or short-acting dihydropyridine calcium antagonists should be avoided as they can increase adverse cardiac events in patients with stable angina 5
• Poor medication adherence is a common cause of treatment failure and should always be assessed in patients with stable angina 5
• An attack of angina that does not respond to short-acting nitroglycerin should be regarded as a possible myocardial infarction in patients with stable angina 4

Order of Anti-Anginal Therapy

Treatment Hierarchy

Priority 1: Medications That Reduce Mortality

• The American College of Cardiology recommends aspirin 75-100 mg daily for all patients without contraindications, as it improves survival 7, 8, 9
• The American Heart Association suggests statin therapy regardless of baseline cholesterol levels, due to its mortality benefits 7, 8

Step 1: First-Line Anti-Anginal Therapy

• The European Society of Cardiology recommends beta-blockers as the preferred initial anti-anginal agent, due to mortality benefits in post-MI patients and proven efficacy in symptom control 7, 8, 9, 10
• The American College of Cardiology states that diabetes is not a contraindication for beta-blockers, and diabetic patients benefit equally or more from their use 7, 8

Step 2: Second-Line Options When Beta-Blockers Fail or Are Contraindicated

• The European Society of Cardiology suggests adding or substituting with dihydropyridine CCB (e.g., amlodipine) if beta-blockers are contraindicated, not tolerated, or symptoms persist despite optimal dosing 10, 11
• The American Heart Association recommends avoiding the combination of verapamil or diltiazem with beta-blockers in patients with heart failure, due to negative inotropic effects 11

Step 3: Third-Line Add-On Therapy

• The European Society of Cardiology recommends considering ranolazine as add-on therapy if symptoms persist despite two anti-anginal drugs, particularly for microvascular angina 10, 9
• The American College of Cardiology suggests considering nicorandil as add-on therapy, but notes that safety data in heart failure is uncertain 10, 11

Step 4: Revascularization

• The European Society of Cardiology recommends coronary revascularization when angina persists despite treatment with two anti-anginal drugs 11

Critical Pitfalls to Avoid

• The American Heart Association warns against combining verapamil or diltiazem with beta-blockers in patients with heart failure, due to negative inotropic effects 11
• The European Society of Cardiology advises against combining ivabradine with non-dihydropyridine CCBs or strong CYP3A4 inhibitors 10
• The American College of Cardiology recommends avoiding the combination of nicorandil with nitrates, as it lacks additional efficacy 11

Special Considerations

• The European Society of Cardiology recommends tailoring selection of anti-anginal therapy based on patient comorbidities, concomitant medications, and underlying pathophysiology 10
• The American Heart Association suggests considering ivabradine as add-on therapy for patients with heart failure and reduced ejection fraction (LVEF <40%) 11

Guideline Summary: Pharmacologic and Revascularization Management of Stable Angina (CCS Class II)

1. Mandatory Primary‑Prevention Therapy

• Aspirin 75–100 mg daily for all patients without contraindications – reduces cardiovascular mortality and morbidity. Class I, high‑quality evidence (American College of Cardiology/American Heart Association) 12.
• High‑intensity statin therapy for every patient regardless of baseline LDL‑C, with a target LDL‑C < 70 mg/dL, shown to lower mortality. Class I, high‑quality evidence (American College of Cardiology/American Heart Association) 12 and (European Society of Cardiology) 13.
• ACE‑inhibitor therapy is recommended in patients who have hypertension, diabetes, heart failure, left‑ventricular ejection fraction < 40 %, or a prior myocardial infarction. Class I, moderate‑quality evidence (American College of Cardiology/American Heart Association) 12.

2. Anti‑anginal Pharmacologic Strategy

2.1 First‑line agents

• Beta‑blockers are the first‑line anti‑anginal drugs, providing mortality benefit in post‑MI patients and effective symptom control. Class I, high‑quality evidence (European Society of Cardiology) 14 and (American College of Cardiology/American Heart Association) 15.
• Target resting heart rate 55–60 beats/min to optimise symptom relief. Class IIa, moderate‑quality evidence (European Society of Cardiology) 14.

Contra‑indications for beta‑blockers – severe chronic obstructive pulmonary disease, sinus bradycardia, atrioventricular block > first degree, sick‑sinus syndrome. Class III, high‑quality evidence (European Society of Cardiology) 14.

2.2 Second‑line agents (when beta‑blockers are unsuitable or insufficient)

• Long‑acting dihydropyridine calcium‑channel blockers (e.g., amlodipine) may be added or substituted. Class IIa, moderate‑quality evidence (European Society of Cardiology) 14.
• Non‑dihydropyridine calcium‑channel blockers (verapamil, diltiazem) are effective alternatives but must not be combined with beta‑blockers in patients with heart failure because of negative inotropic effects. Class IIa, moderate‑quality evidence (European Society of Cardiology) 14.

2.3 Add‑on therapies for refractory angina

• Ranolazine can be added, particularly for microvascular angina. Class IIb, moderate‑quality evidence (European Society of Cardiology) 14.
• Ivabradine is not recommended as an add‑on in patients with ejection fraction > 40 % and without clinical heart failure. Class III, moderate‑quality evidence (European Society of Cardiology) 15.

2.4 Immediate symptom relief

• Sublingual nitroglycerin is mandatory for all patients for rapid relief of angina episodes and for prophylaxis before known triggers. Class I, high‑quality evidence (European Society of Cardiology) 15.

2.5 Drug interaction cautions

• Do not combine ivabradine with non‑dihydropyridine calcium‑channel blockers or strong CYP3A4 inhibitors. Class III, moderate‑quality evidence (European Society of Cardiology) 15.

3. Lifestyle Modifications (Evidence‑Based)

• Smoking cessation – the most impactful modifiable risk factor on mortality. Class I, high‑quality evidence (European Society of Cardiology) 16.
• Aerobic physical activity – 150–300 min/week of moderate intensity or 75–150 min/week of vigorous intensity improves outcomes. Class I, moderate‑quality evidence (European Society of Cardiology) 15.
• Strict glycaemic control in diabetic patients reduces cardiovascular events. Class I, high‑quality evidence (American College of Cardiology/American Heart Association) 12.

4. Indications for Revascularization

• Coronary angiography should be performed when:

• Coronary artery bypass grafting (CABG) reduces mortality in high‑risk subgroups:

• Percutaneous coronary intervention (PCI) is effective for anatomically suitable lesions when symptoms are not adequately controlled with medical therapy. Class IIa, moderate‑quality evidence (European Society of Cardiology) 16.

All bullet points are supported by at least one cited reference and reflect the strength of evidence where reported.